

Title page

Long term follow-up of the Intergroup Exemestane Study (IES)

James P Morden¹, Isabel Alvarez², Gianfilippo Bertelli³, Alan S Coates⁴, Robert Coleman⁵, Lesley Fallowfield⁶, Jacek Jassem⁷, Stephen Jones⁸, Lucy Kilburn¹, Per E. Lønning⁹, Olaf Ortmann¹⁰, Claire Snowdon¹, Cornelis van de Velde¹¹, Jørn Andersen¹², Lucia Del Mastro¹³, David Dodwell¹⁴, Stig Holmberg¹⁵, Hanna Nicholas¹⁶, Robert Paridaens¹⁷, Judith M Bliss^{1*} and R. Charles Coombes^{18*}

*- Joint corresponding authors

Author affiliations

- 1 – The Institute of Cancer Research, London, United Kingdom
- 2 - Hospital Donostia, San Sebastian, Spain
- 3 – Singleton Hospital, Swansea, United Kingdom
- 4 - International Breast Cancer Study Group, Bern, Switzerland, and University of Sydney, Sydney, Australia
- 5 - Weston Park Hospital, Sheffield, United Kingdom
- 6 - University of Sussex, Brighton, United Kingdom
- 7 - Medical University of Gdansk, Gdansk, Poland
- 8 - US Oncology Research, The Woodlands, TX, USA
- 9 – Department of Clinical Science, University of Bergen and Department of Oncology, Haukeland, University Hospital, Bergen, Norway
- 10 - University Medical Center Regensburg, Regensburg, Germany
- 11 - Leiden University Medical Centre, Leiden, the Netherlands
- 12 - Aarhus University Hospital, Aarhus, Denmark
- 13 - IRCCS AOU San Martino –IST, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy
- 14 - St James Hospital, Leeds, United Kingdom
- 15 - SU/Goteborg, Kirurgiska kliniken, Goteborg, Sweden
- 16 – Cancer Research UK, London, United Kingdom
- 17 - Universitair Ziekenhuis Gasthuisberg, Leuven, Belgium
- 18 - Imperial College London, London, United Kingdom

Joint corresponding authors:

R. Charles Coombes

Judith Bliss

Division of Cancer
Department of Surgery & Cancer
1st Floor ICTEM Building Imperial College
London
Du Cane Road London
W12 0NN

ICR-CTSU
Division of Clinical Studies
The Institute of Cancer Research
15 Cotswold Road
Sutton
SM2 5NG

Tel: 0207 594 2761
Fax: 0203 313 5830

Tel: 0208 722 4297
Fax: 0208 770 7876

Research supported by Pfizer Inc.

Running head: Long term follow-up of the Intergroup Exemestane Study (IES)

Abstract

Purpose

The Intergroup Exemestane Study (IES), an investigator-led study in 4724 postmenopausal patients with early breast cancer (ISRCTN11883920), has previously demonstrated that switching adjuvant endocrine therapy after 2-3 years tamoxifen to exemestane is associated with clinically relevant improvements in efficacy. Here we report the final efficacy analyses of this cohort.

Patients and methods

Patients who remained disease-free after 2-3 years of adjuvant tamoxifen were randomized to continue tamoxifen (T) or switch to exemestane (E) to complete a total of 5 years adjuvant endocrine therapy. Given the large number of non-breast cancer deaths now reported, breast-cancer-free survival (BCFS), censoring intercurrent deaths, is the primary survival endpoint of interest. Analyses focus on patients with ER positive (+) or unknown tumors (n=4599).

Results

At the time of data snapshot, median follow-up was 120 months. In the ER+/unknown population, 1111 BCFS events were observed, 508/2294 (22.1%) and 603/2305 (26.2%) in E and T groups respectively, corresponding to absolute difference (E-T) at 10 years of 4.0% (95%CI 1.2%-6.7%), with hazard ratio (HR) of 0.81 (95% CI 0.72-0.92) favoring E. This difference remained in multivariable analysis adjusting for nodal status, prior use of HRT and chemotherapy (HR=0.80 (95%CI 0.71-0.90); p<0.001).

A modest improvement in overall survival was seen with E, with absolute difference (E-T) at 10 years in the ER+/unknown population of 2.1% (95%CI -0.5%-4.6%), HR=0.89 (95%CI

0.78-1.01, $p=0.08$). For the ITT population, absolute difference was 1.6% (95%CI -0.9%-4.1%), HR=0.91 (95%CI 0.80-1.03, $p=0.15$).

Conclusions

The IES and contemporaneous studies have established that a strategy of switching to an aromatase inhibitor after 2-3 years of tamoxifen can lead to sustained benefits in terms of reduction of disease recurrence and breast cancer mortality.

Introduction

Despite improvements in adjuvant treatment, breast cancer remains the most frequent cause of cancer-related death in women, with approximately 508,000 deaths reported worldwide in 2011¹. For patients diagnosed with ER positive disease, risk of disease relapse remains for over 15 years after initial diagnosis, with recent research demonstrating the cumulative risk of relapse at 15 years to be comparable to that of ER negative patients in those receiving chemotherapy².

Aromatase inhibitors reduce recurrence rates and 10-year breast cancer mortality rates compared with tamoxifen, but the optimal way to schedule aromatase inhibitors is still debated³.

The Intergroup Exemestane Study (IES) was an investigator-led, Pfizer sponsored trial assessing the impact on disease related outcome, adverse events, and quality of life of switching to exemestane after 2-3 years of tamoxifen compared with continuing to 5 years of tamoxifen⁴⁻¹¹. The most recent update of efficacy analyses published in 2012 (data snapshot December 7, 2009) after a median follow-up of 91 months demonstrated that the highly statistically significant benefit of switching to exemestane on disease-free survival observed at initial publication was maintained, and this translated to a modest improvement in overall survival⁶.

IES was the first trial published to describe the benefits of switching from tamoxifen to an AI (exemestane) at 2-3 years, and was one of the pivotal generation of trials assessing the role of aromatase inhibitors in combination with or as a replacement for standard tamoxifen

treatment³. Whether the strategy results in long-term sustained improvement in DFS or survival remains controversial, although our previous report suggested that this was the case⁶.

Recent analyses of the ATAC trial have sought to identify clinical and biological factors associated with disease relapse after completion of endocrine therapy^{12,13}. Nodal involvement and tumor size are the most important clinical factors for predicting relapse both during and post treatment completion in ER positive breast cancer patients^{14,15}. The other aim of this study, therefore, was to establish which prognostic features were important in the IES trial, which employed a 'switching' strategy, especially after the end of endocrine therapy.

Here we present the final efficacy analysis of the IES, along with exploratory analyses investigating clinical factors affecting the risk of distant relapse after completion of endocrine therapy.

Methods

Details of trial design, eligibility criteria and study procedures have been presented previously⁴⁻⁶. Briefly, eligible patients were post-menopausal women with ER+/unknown primary invasive breast cancer who remained disease free and on treatment after 2-3 years of tamoxifen. At randomisation women were allocated to continue tamoxifen (20 mg or [30 mg in Denmark] daily) or to switch to exemestane (25 mg daily) for the remainder of the 5 year endocrine therapy period. Timing of analyses was pre-planned, triggered by the last patient randomised reaching their 10 year follow-up. The current analysis includes all data received as of the 4th September 2013.

Efficacy analyses presented here have been performed on the main IES analysis population, which includes patients whose tumors were ER+ve (4052, 85.8%) plus those whose ER status remains unknown (547, 11.6%). Analyses exclude 125 patients (2.6%) with ER-negative disease, who would not have been eligible for the trial had their receptor status been known at trial entry. Intention to treat (ITT) analysis of OS is included for completeness.

Statistical analysis

The primary endpoint of the IES was DFS, defined as time from randomisation to local or distant breast cancer recurrence, new primary breast cancer or death without disease relapse (intercurrent death). As reported previously⁶, the proportion of patients experiencing intercurrent death has increased as the IES population ages, decreasing the sensitivity of DFS to detect differences between treatments in breast cancer outcome. Therefore we now regard breast cancer free survival (BCFS) in which intercurrent deaths are censored, as providing a more direct estimate of the treatment effect on breast cancer outcome in the long term. Other secondary endpoints presented include overall survival (OS, defined as time from randomisation to death from any cause), breast cancer specific survival (BCSS, defined as time from randomisation to breast cancer death (including death from unknown cause and other cause after recurrence), time to contralateral breast cancer (CLB, defined as time to contralateral breast cancer with patients censored at time of non-breast second primary cancer) and time to distant recurrence (TTDR, defined as time to distant recurrence or death from breast cancer or unknown cause without prior recurrence).

Kaplan-Meier plots, log-rank tests and Cox proportional hazards analyses were used to compare survival endpoints between randomised treatment groups. Multivariable analysis

adjusting for known prognostic factors of nodal status, chemotherapy use and HRT use was also conducted.

For description of the sites of first distant recurrence the following groupings were used: visceral, bone or soft tissue/nodal, with patients assigned to multiple groups where relevant. Progression of metastatic disease subsequent to the initial distant recurrence was ignored. Events where site of recurrence was unknown were excluded from this part of the analysis.

The overall and age-related incidence of non-breast cancer second primary cancers was investigated to confirm the observation in our previous reports of a differential pattern according to randomised treatment^{5,6}. For patients who reported more than one non-breast second primary cancer (n=6), the first reported event was included. Second primaries reported with no confirmed date of diagnosis were excluded (n=8).

Competing risks analyses were undertaken to assess the impact of randomised treatment on breast cancer events (local recurrence, distant recurrence, CLB, ipsilateral breast cancer (ILB), and BC death or death from unknown cause) whilst allowing for “competing risks” of intercurrent death and non-breast second primary cancer. Patients were included depending on which event occurred first; breast cancer event or competing risk event. Gray’s test was used to compare the two treatment groups with respect to breast cancer event in the presence of competing risks¹⁶.

Landmark analyses were performed to investigate the factors related to distant recurrence after the end of endocrine therapy. TTDR was the endpoint of interest, with survival time being partitioned at 2.5 years, representing the approximate end of endocrine therapy in IES.

The impact of randomised treatment and a number of patient and tumor characteristics on TTDR after 2.5 years was assessed, both as single variables and together in a multivariable Cox proportional hazards model.

Full adverse event^{4-7,11} and quality of life^{9,10} data have been reported previously and are therefore not included in this manuscript, but we present here an updated estimate of post-treatment fracture incidence by treatment received. This includes all fractures occurring more than 6 months after treatment completion in patients who received at least 1 day of treatment, with events censored following relapse or new second primary cancer.

Analyses were performed using STATA version 13.2, (STATA Corp, College Station, TX). All statistical tests were two-sided with $p < 0.05$ considered statistically significant.

Results

Between 1998 and 2003, 4724 evaluable patients were randomised from 366 sites in 37 countries. Of these, 4599 are known to be ER+ve or have unknown ER status (Figure 1).

Patient characteristics have previously been reported and were well balanced between treatment groups^{5,6}. In summary, 2089/4724 (44.2%) patients were node positive and 1542/4724 (32.6%) patients had received adjuvant chemotherapy. Mean age at randomisation was 64.2 years (SD=8.2). At the time of data snapshot (04/09/2013) median follow-up in patients still known to be alive was 120.0 months (IQR: 114.8 to 122.0, range: 2.9 to 164.1), with current analysis based on over 39,000 women-years of follow-up. 74.7% of patients had at least 10 years follow-up or had previously died.

Efficacy

In the ER+ve/unknown population, 1111/4599 patients have experienced a BCFS event (exemestane 508/2294 (22.1%), tamoxifen 603/2305 (26.2%)). A reduction in risk of breast cancer related events was observed with an absolute difference at 10 years of 4.0% (95% CI 1.2% to 6.7%) and a hazard ratio of 0.81 (95% CI 0.72 to 0.92) in favor of switching to exemestane (Figure 2a).

In the ER+ve/unknown population, 940/4599 patients have died (exemestane 445/2294 (19.4%), tamoxifen 495/2305 (21.5%)). A modest improvement in OS was seen with exemestane, with an absolute survival difference at 10 years of 2.1% (95% CI -0.5% to 4.6%) and a hazard ratio of 0.89 (95% CI 0.78 to 1.01) in favor of switching to exemestane, Figure 2b. The numerical difference in deaths was mainly seen in deaths due to breast cancer, with rates of intercurrent deaths similar between randomised treatment groups (Table 1). Results were similar when considering the ITT population (exemestane 467/2352 (19.9%), tamoxifen 510/2372 (21.5%), HR=0.91 (95% CI 0.80 to 1.03), Figure 2c.

In the ER+ve/unknown population, 659/4599 BCSS events were reported (exemestane 303/2294 (13.2%), tamoxifen 356/2305 (15.4%)). Absolute BCSS difference at 10 years was 2.3% (95% CI -0.0% to 4.6%) with a hazard ratio of 0.84 (95% CI 0.72 to 0.98) in favor of switching to exemestane, Figure 2d.

1392 DFS events have been reported in ER+/unknown patients only (exemestane 650/2294 (28.3%), tamoxifen 742/2305 (32.2%)). The highly significant improvement in DFS associated with switching to exemestane that we noted previously remains, with no convergence of survival curves seen (Figure 2e). This sustained benefit translated to an

absolute difference in the proportion remaining alive and disease-free at 10 years of 3.8% (95%CI 0.9%, 6.6%). This difference remained in multivariable analyses adjusting for nodal status, prior HRT use and prior chemotherapy (HR favoring switch to exemestane of 0.83 (95%CI 0.75 to 0.93); $p=0.001$).

Using competing risks methodology, investigating all outcomes in a single analysis, the cumulative incidence of intercurrent deaths was seen to increase steadily throughout the follow-up period and was comparable between randomised treatment groups (Figure 3). Considering breast cancer events (after adjustment for competing risks), the early benefit from switching to exemestane was maintained throughout follow-up (Gray's test $p=0.002$).

No statistically significant difference was seen between randomised groups in the number of patients reporting a new primary CLBC (exemestane 56; tamoxifen 75; HR=0.73, 95% CI 0.52-1.03, Table 1) although the observed hazard ratio is consistent with other trials which have explored the additional preventative benefits of aromatase inhibitors compared with tamoxifen¹⁷. Numerically fewer non-breast second primary cancers were also reported with exemestane (143, compared to 191 with tamoxifen, Table 1). Analyses of incidence of distant recurrence and non-breast second primary cancer by age at randomisation reflect data presented previously, with a suggestion that second primary cancer incidence increases with age but no association was seen between age and distant recurrence incidence (trend tests $p=0.08$ and 0.22 respectively, Appendix 1).

Results of TTDR analyses across the entire follow-up period reflected other efficacy endpoints, with an absolute difference in the rate of distant recurrence or breast cancer death at 10 years of 2.6% (95% CI 0.2% to 5.1%) and a hazard ratio of 0.84 (95% CI 0.74 to 0.96)

in favor of switching to exemestane. Analyses of TTDR after completion of endocrine therapy – equivalent to approximately 5 years after diagnosis - include 4147 patients (2091 exemestane, 2056 tamoxifen) known to be event free at 2.5 years post-randomisation (Table 2). No statistically significant difference in TTDR during this period was observed between randomised treatment groups (HR=0.94, 95% CI 0.80 to 1.10, p=0.41), reflecting the observation that the initial difference in disease outcome observed in the on-treatment period is maintained throughout the follow-up period. After inclusion in a multivariable Cox proportional hazards model, age at randomisation, nodal status, hormone receptor status, previous HRT use and tumor size, but not grade, had a significant effect on the risk of TTDR event after completion of endocrine therapy, i.e. of late relapse. Of note, risk of late distant recurrence in patients with tumor size greater than 5 cm at diagnosis was almost double that of patients with tumors of less than 2 cm (HR=1.92, 95% CI 1.28 to 1.90), and over six times higher in patients with 10 or more nodes involved compared to those who were node-negative at randomisation (HR=6.10, 95% CI 4.41 to 8.44), after adjustment for other factors.

Fractures

No statistically significant difference was seen in the proportion of patients reporting at least one fracture event in the post-treatment period (exemestane 196/2105 (9.3%), tamoxifen 163/2036 (8.0%), p=0.14).

Discussion

This updated and final analysis of IES demonstrates that the benefit associated with switching to exemestane observed early in the follow-up period remains undiminished by further follow-up. As the IES population ages, incidence of non-breast cancer deaths and non-breast second primary cancers increase, leading to a dilution of OS results, however a modest

benefit from switching to exemestane can still be seen, with absolute difference in OS at 10 years post-randomisation of 1.6%. As suggested previously, BCFS (which does not include non-breast cancer deaths) remains the most appropriate measure of treatment efficacy in this setting; an absolute benefit of 4.0% from switching to exemestane was observed at 10 years. Analyses taking into account competing events of intercurrent death and non-breast second primary cancer showed an absolute difference in breast cancer event at 10 years of 3%.

The IES trial compared treatments up to 5 years' duration. Recent large randomised controlled trials¹⁸⁻²⁰ have demonstrated an improvement in disease-related outcomes associated with continuing tamoxifen or aromatase inhibitor treatment past the standard five years of treatment. However long-term use of endocrine therapy is associated with many side-effects some of which have substantial impacts on patient well-being such as osteoporosis, vasomotor problems and musculo-skeletal conditions²¹. There remains great clinical need to identify patients who remain at high risk of disease relapse after completion of 5 years of endocrine therapy who may benefit from further treatment, and conversely patients who may be spared this due to low residual risk.

Results of analyses partitioned at 2.5 years post-randomisation support conclusions made previously that the difference in disease-related outcome observed at 10 years between treatment groups is due to maintenance of the initial on-treatment divergence between groups rather than any emerging post-treatment effect. Multivariable analyses of clinical factors affecting time to late distant recurrence identified age at randomisation, nodal involvement, hormone receptor status, previous HRT use and tumor size, although the relationship between HRT use and late distant recurrence is confounded by geographical region. The observation that tumor grade no longer retains prognostic significance in this setting after adjustment for

other factors reflects previous analyses of retrospective case-series²² and comparable analyses of the ATAC trial¹². The authors of this analysis also demonstrated the value of the PAM50-based risk of recurrence (ROR) score as an independent predictor of late distant recurrence; other molecular scores studied (IHC4, RS) did not add prognostic information when added to clinical data¹³.

In summary, the IES and other contemporaneous studies have established that a strategy of switching to an aromatase inhibitor after 2-3 years of tamoxifen can lead to sustained benefits in terms of reduction of disease recurrence and breast cancer mortality. Identifying patients who remain at higher risk of disease recurrence after the completion of 5 years of endocrine therapy (be it tamoxifen, aromatase inhibitor or a combination of the two) according to clinical factors such as nodal involvement and tumor size will aid decision making on the administration of further endocrine therapy or additional therapeutic agents.

References

1. W H: Breast cancer: prevention and control, 2013
2. Early Breast Cancer Trialists' Collaborative G: Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. *Lancet* 365:1687-717, 2005
3. Early Breast Cancer Trialists' Collaborative G, Dowsett M, Forbes JF, et al: Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. *Lancet* 386:1341-52, 2015
4. Coombes RC, Hall E, Gibson LJ, et al: A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. *N Engl J Med* 350:1081-92, 2004
5. Coombes RC, Kilburn LS, Snowdon CF, et al: Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. *Lancet* 369:559-70, 2007
6. Bliss JM, Kilburn LS, Coleman RE, et al: Disease-related outcomes with long-term follow-up: an updated analysis of the intergroup exemestane study. *J Clin Oncol* 30:709-17, 2012
7. Coleman RE, Banks LM, Girgis SI, et al: Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. *Lancet Oncol* 8:119-27, 2007
8. Bertelli G, Hall E, Ireland E, et al: Long-term endometrial effects in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES)--a randomised controlled trial of exemestane versus continued tamoxifen after 2-3 years tamoxifen. *Ann Oncol* 21:498-505, 2010
9. Fallowfield LJ, Bliss JM, Porter LS, et al: Quality of life in the intergroup exemestane study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer. *J Clin Oncol* 24:910-7, 2006
10. Fallowfield LJ, Kilburn LS, Langridge C, et al: Long-term assessment of quality of life in the Intergroup Exemestane Study: 5 years post-randomisation. *Br J Cancer* 106:1062-7, 2012
11. Mieog JS, Morden JP, Bliss JM, et al: Carpal tunnel syndrome and musculoskeletal symptoms in postmenopausal women with early breast cancer treated with exemestane or tamoxifen after 2-3 years of tamoxifen: a retrospective analysis of the Intergroup Exemestane Study. *Lancet Oncol* 13:420-32, 2012
12. Sestak I, Dowsett M, Zabaglo L, et al: Factors predicting late recurrence for estrogen receptor-positive breast cancer. *J Natl Cancer Inst* 105:1504-11, 2013
13. Dowsett M, Sestak I, Buus R, et al: Estrogen Receptor Expression in 21-Gene Recurrence Score Predicts Increased Late Recurrence for Estrogen-Positive/HER2-Negative Breast Cancer. *Clin Cancer Res* 21:2763-70, 2015
14. Martin M, Pienkowski T, Mackey J, et al: Adjuvant docetaxel for node-positive breast cancer. *N Engl J Med* 352:2302-13, 2005
15. Roche H, Fumoleau P, Spielmann M, et al: Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial. *J Clin Oncol* 24:5664-71, 2006
16. Pintile M: *Competing Risks: A Practical Perspective*, Wiley, 2006
17. Cuzick J, Sestak I, Forbes JF, et al: Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. *Lancet* 383:1041-8, 2014
18. Davies C, Pan H, Godwin J, et al: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. *Lancet* 381:805-16, 2013
19. Gray RG, Rea D, Handley K, et al: aTTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer. *J Clin Oncol (Meeting Abstracts)* 31:5-, 2013

20. Goss PE, Ingle JN, Pritchard KI, et al: Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years. *N Engl J Med* 375:209-19, 2016
21. Lonning PE, Eikesdal HP: Aromatase inhibition 2013: clinical state of the art and questions that remain to be solved. *Endocr Relat Cancer* 20:R183-201, 2013
22. Brewster AM, Hortobagyi GN, Broglio KR, et al: Residual risk of breast cancer recurrence 5 years after adjuvant therapy. *J Natl Cancer Inst* 100:1179-83, 2008

Acknowledgements

We thank the women who took part in this study, the doctors, nurses, and support staff at local sites, and the monitors, data managers, trial coordinators, and study managers from the Argentine Breast Cancer Group, the Australian New Zealand Breast Cancer Trials Group, the Central and Eastern European Oncology Group, the Danish Breast Cancer Group, the Dutch Breast Cancer Research Group, the European Organisation for Research and Treatment of Cancer, the Grupo Espanol De Investigacion Del Cancer De Mama, the Gruppo Oncologico Nord Ovest, the Gruppo Oncologico Italiano di Ricerca Clinica, the International Breast Cancer Study Group, the International Collaborative Cancer Group, the Israeli Clinical Oncology Group, Italian Trials in Medical Oncology, the North West England Group, the Norwegian Breast Cancer Group, the Yorkshire Breast Group, the Federation Nationale Des Centres De Lutte Contre Le Cancer, the German Exemestane Adjuvant Group, the Wales Cancer Trials Network, US Oncology, the Swedish Breast Cancer Group and Pfizer. We also thank the Breast International Group for their support and the members of the study steering committee and the independent data monitoring committee. The trial coordinating units at Imperial College London and The Institute of Cancer Research also received funding from Cancer Research UK.

Table and figure legends

Figure 1 = CONSORT diagram

Figure 2a = Breast cancer free survival in the ER+/unknown population (N=4599)

Figure 2b = Overall survival in the ER+/unknown population (N=4599)

Figure 2c = Overall survival in the ITT population (N=4724)

Figure 2d = Breast cancer specific survival in the ER+/unknown population (N=4599)

Figure 2e = Disease free survival in the ER+/unknown population (N=4599)

Figure 3 = Cumulative incidence of breast cancer event and of the competing risks
intercurrent death and non-breast second cancer

Table 1 = Efficacy events by treatment group in the ER+ve/unknown population (N=4599)

Table 2 = Factors affecting risk of TTDR event after 2.5 years

Appendix 1 – Distant recurrence and non-breast second primary incidence by age

Figure 1: CONSORT diagram





Figure 2a: Breast cancer free survival (ER+ve/Unknown population, N=4599)



Number of events/at risk

	0	1	2	3	4	5	6	7	8	9	10	11
Exe	0/2294	55/2193	59/2125	80/2018	70/1919	67/1822	63/1721	51/1643	77/1523	58/1393	53/890	17+0*/35
Tam	0/2305	81/2193	101/2077	98/1948	69/1847	65/1753	72/1651	67/1551	63/1442	49/1333	58/842	19+0*/41

* events occurring after 11 years

Figure 2b: Overall survival (ER+ve/Unknown population, N=4599)




Figure 2c: Overall survival (ITT population, N=4724)




Figure 2d: Breast cancer specific survival (ER+ve/Unknown population, N=4599)





Figure 2e: Disease-free survival (ER+ve/Unknown population, N=4599)



Number of events/at risk		0	1	2	3	4	5	6	7	8	9	10	11
Exe	0/2294	55/2193	59/2125	80/2018	70/1919	67/1822	63/1721	51/1643	77/1523	58/1393	53/890	17+0*/35	
Tam	0/2305	81/2193	101/2077	98/1948	69/1847	65/1753	72/1651	67/1551	63/1442	49/1333	58/842	19+0*/41	

* events occurring after 11 years

Figure 3: Cumulative incidence of breast cancer event in the presence of competing risks




Table 1: Efficacy events by treatment group in the ER+ve/unknown population (N=4599)

Number of events contributing to endpoint of interest	ER+/unknown population		
	Exemestane (N=2294)	Tamoxifen (N=2305)	Total (N=4599)
<i>DFS First events</i>	650 (28.3%)	742 (32.2%)	1392 (30.3%)
Total BCFS events	508	603	1111
Distant recurrence	369	420	789
Local recurrence	81	109	190
Second primary breast cancer	58	74	132
Intercurrent death	142	139	281
<i>All deaths</i>	445 (19.4%)	495 (21.5%)	940 (20.4%)
Breast cancer death	263	310	573
Death unknown cause	40	46	86
Death from other known cause	142	139	281
Other cancer	40	60	100
Vascular	36	23	59
Cardiac	30	23	53
Other	36	33	69
<i>Distant recurrences</i>	403 (17.6%)	469 (20.4%)	872 (19.0%)
Distant recurrence to known site	346	393	739
Visceral only	129	130	259
Soft tissue/Nodal only	29	25	54
Visceral+Soft tissue/Nodal	15	18	33
Total sites not including bone	173	173	346
Bone only	87	127	214
Visceral+Bone	60	63	123
Visceral + Bone + Soft tissue/Nodal	15	18	33
Bone + Soft tissue/Nodal	11	12	23
Total sites including bone	173	220	393
BC death no previous recurrence	17	28	45
Death from unknown cause	40	48	88
<i>Contralateral breast cancers</i>	56 (2.4%)	75 (3.3%)	131 (2.8%)
<i>Non-breast second primary cancers</i>	143 (6.2%)	191 (8.3%)	334 (7.3%)
Uterus	15	28	43
GI-upper	24	20	44
GI-lower	20	28	48
Lung	14	29	43
Melanoma	10	9	19
Ovary	10	8	18
Hematological	15	17	32
Kidney	5	8	13
Other	30	44	74

Table 2: Factors affecting risk of TTDR event after 2.5 years (i.e. approximately 5 years after diagnosis)

	N	TTDR events	%	Unadjusted analysis			Adjusted analysis (not including geographical region)			Adjusted analysis (including geographical region)			
				HR	95% CI	p-value*	HR	95% CI	p-value*	HR	95% CI	p-value*	
Randomised treatment													
Tamoxifen	2056	311	15.1	1	-	0.41	1	-	0.29	1	-	0.32	
Exemestane	2091	300	14.3	0.94	0.80 - 1.10		0.92	0.78 - 1.08		0.92	0.79 - 1.08		
Age at randomisation													
<60	1352	187	13.8	1	-		1	-		1	-		
60-69	1548	248	16.0	1.01	0.84 - 1.22	0.0003	1.03	0.85 - 1.25	0.008	1.05	0.86 - 1.27	0.004	
>=70	999	176	17.6	1.43	1.17 - 1.76		1.36	1.09 - 1.70		1.41	1.13 - 1.76		
Nodal status													
N-	2227	183	8.2	1	-		1	-		1	-		
1-3N+	1256	220	17.5	2.22	1.83 - 2.70		2.11	1.72 - 2.59		2.09	1.70 - 2.56		
4-9N+	386	131	33.9	4.8	3.84 - 6.01	<0.0001	4.41	3.45 - 5.63	<0.0001	4.28	3.35 - 5.46	<0.0001	
>=10N+	119	57	47.9	7.57	5.63 - 10.21		6.10	4.41 - 8.44		6.07	4.38 - 8.40		
Unknown	159	20	12.6	1.59	1.01 - 2.53		1.63	1.02 - 2.60		1.82	1.14 - 2.92		
Previous chemotherapy use													
Yes	1305	248	19.0	1	-	<0.0001	1	-	0.48	1	-	0.58	
No	2842	363	12.8	0.66	0.56 - 0.77		1.07	0.89 - 1.30		1.06	0.87 - 1.28		
Hormone receptor status													
ER+ and PgR+	2474	331	13.4	1	-		1	-		1	-		
ER+ and PgR-/unknown	1204	206	17.1	1.3	1.09 - 1.55	0.008	1.29	1.08 - 1.54	0.01	1.33	1.11 - 1.60	0.006	
ER unknown and PgR unknown	469	74	15.8	1.24	0.96 - 1.59		1.22	0.94 - 1.58		1.22	0.93 - 1.61		

	N	TTDR events	%	Unadjusted analysis			Adjusted analysis (not including geographical region)			Adjusted analysis (including geographical region)		
				HR	95% CI	p-value*	HR	95% CI	p-value*	HR	95% CI	p-value*
Histological type												
Ductal	3157	450	14.3	1	-		1	-		1	-	
Lobular	578	108	18.7	1.32	1.07 - 1.62	0.02	1.16	0.93 - 1.45	0.30	1.17	0.94 - 1.46	0.29
Other/Unknown	412	53	12.9	0.87	0.65 - 1.16		0.93	0.69 - 1.24		0.93	0.70 - 1.25	
Previous HRT use												
Yes	1021	115	11.3	1	-		1	-		1	-	
No	3035	473	15.6	1.47	1.20 - 1.80	<0.0001	1.35	1.10 - 1.67	0.006	1.20	0.97 - 1.49	0.09
Unknown	91	23	25.3	2.38	1.52 - 3.72		1.74	1.10 - 2.74		1.59	1.00 - 2.52	
Tumor size (cm)												
<=2	2537	277	10.9	1	-		1	-		1	-	
>2 & <=5	1431	292	20.4	2.03	1.72 - 2.39	<0.0001	1.51	1.28 - 1.80	<0.0001	1.51	1.27 - 1.79	<0.0001
>5	94	26	27.7	3.05	2.04 - 4.56		1.92	1.28 - 1.90		1.96	1.30 - 2.96	
Unknown	85	16	18.8	1.76	1.07 - 2.92		1.35	0.80 - 2.25		1.28	0.77 - 2.15	
Tumor grade												
G1	737	73	9.9	1	-		1	-		1	-	
G2	1785	263	14.7	1.52	1.17 - 1.97	0.0001	1.16	0.89 - 1.51	0.40	1.14	0.88 - 1.49	0.69
G3/Undifferentiated	756	120	15.9	1.66	1.24 - 2.22		1.16	0.86 - 1.56		1.13	0.84 - 1.53	
Unknown	869	155	17.8	1.91	1.45 - 2.52		1.29	0.96 - 1.72		1.20	0.89 - 1.61	
Region												

	N	TTDR events	%	Unadjusted analysis			Adjusted analysis (not including geographical region)			Adjusted analysis (including geographical region)		
				HR	95% CI	p-value*	HR	95% CI	p-value*	HR	95% CI	p-value*
USA	325	26	8.0	0.53	0.35 - 0.79	<0.0001				0.67	0.45 - 1.02	0.02
UK	512	54	10.5	0.63	0.47 - 0.84					0.69	0.51 - 0.94	
Central & Eastern Europe	754	134	17.8	1.20	0.98 - 1.46					1.15	0.93 - 1.44	
Rest of Europe	2351	367	15.6	1	-					1	-	
Southern Hemisphere & Hong Kong	205	30	14.6	1.01	0.70 - 1.47					0.96	0.66 - 1.40	

*- p-value for Likelihood ratio test. p-values are calculated with “unknown” categories included.